Navigation Links
MD Anderson announces immunotherapy collaboration with GSK
Date:4/8/2014

HOUSTON The University of Texas MD Anderson Cancer Center announced today it formed a research alliance with GlaxoSmithKline (GSK), a global leader in pharmaceutical development, to strengthen its efforts in advancing therapies that train the body's immune system to combat cancer.

The collaboration completes an ambitious plan to partner with leading pharmaceutical companies to more rapidly develop cancer immunotherapies as part of MD Anderson's Moon Shots Program. Through this venture, GSK and MD Anderson will work together to identify new therapeutic approaches, evaluate patient responses in clinical trials and use those insights to develop immunotherapy drugs.

"With this agreement, we've now completed our fourth and final major collaboration with large companies who share our commitment to deliver on the promise of immunotherapy, using the resources of our immunotherapy platform," said Ferran Prat, Ph.D., J.D., and vice president of MD Anderson Strategic Industry Ventures. "We're also committed to help leading start-ups establish a foothold in this exciting field, but collaborating with this select group of highly committed companies will help bring new therapies to patients faster."

"This collaboration brings together MD Anderson's basic science capabilities with GSK's drug discovery and development expertise, and our growing immuno-oncology portfolio," said Axel Hoos, M.D., Ph.D., VP Oncology R&D, who leads GSK's immuno-oncology programs and has previous experience working with MD Anderson in this field. "The alliance will build on the strengths of both organizations to innovate in translational research, which will enhance drug development programs in this fast-growing area." Hoos developed the first immune checkpoint modulatory antibody (anti-CTLA-4) in a previous partnership with MD Anderson's Jim Allison, Ph.D.

MD Anderson recognized the potential of immune-based therapies by creating one of the platforms that su
'/>"/>

Contact: William Fitzgerald
wbfitzgerald@mdanderson.org
713-792-9518
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. MD Anderson honors 2 champions for women in medicine and research
2. MD Anderson, MedImmune join forces to advance cancer immunotherapy
3. MD Anderson researcher uncovers some of the ancient mysteries of leprosy
4. Bevacizumab offers no benefit for newly diagnosed glioblastoma, MD Anderson-led study finds
5. MD Anderson guides intelligent redesign of cancer care delivery model
6. MD Anderson researcher Jim Allison wins Breakthrough Prize for his innovative cancer immunology rese
7. 4 from UT MD Anderson named Fellows in AAAS
8. Super Bowl Champion OJ Anderson Treated By Pro Player Health Alliance For Sleep Apnea With A Dental Device
9. Sleep Apnea Treatment Becoming More Popular in New York After Long Island Dental Sleep Medicine Begins Treatment on OJ Anderson, Giants Super Bowl Champion
10. Colleen’s Dream Foundation Gifts $10,000 to The University of Texas MD Anderson Cancer Center to Support Ovarian Cancer Research
11. MD Anderson educators win AEIRS/Elsevier Innovator of the Year Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... The North America Phytochemicals & Plant Extracts Market ... in North America with analysis and forecast of revenue. This ... in 2012 to $930.1 million by 2018, at a CAGR ... TOC of the North America phytochemicals & plant extracts market ... It also provides a glimpse of the segmentation in the ...
(Date:7/31/2014)... The North American Colorants Market ... North America with analysis and forecast of volume ... North American Colorants Market report, to get an ... provides a glimpse of the segmentation in the ... various tables and figures. , http://www.micromarketmonitor.com/market/americas-colorants-8463333110.html ...
(Date:7/31/2014)... 2014 (HealthDay News) -- Many teens never outgrow their ... pain can persist for years, affecting teens, participation in ... left untreated, so-called growing pains can become chronic, the ... that one in three young people between the ages ... their knees," said Michael Skovdal Rathleff, a physiotherapist from ...
(Date:7/31/2014)... 2014 i2i Systems announced today it ... (SAS) to provide a robust patient referral database ... is one of the largest independent software companies in ... 40,000 patients are seen annually in its on-site HCC ... primary care, providers at the SAS HCC refer patients ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 With the brand ... a new lecture series featuring the “reality model” ... National Park, a more affordable resort pricing structure, and a ... Co-founder, says, “We have always had a great weight loss ... that differentiate Fitness Ridge. We want to change the way ...
Breaking Medicine News(10 mins):Health News:North America Phytochemicals & plant extracts (Nutraceuticals) Market is Expected to Reach $930.1 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Phytochemicals & plant extracts (Nutraceuticals) Market is Expected to Reach $930.1 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Phytochemicals & plant extracts (Nutraceuticals) Market is Expected to Reach $930.1 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Americas Colorants Market is Expected to Reach 2,006 Thousand MT in 2018 - New Report by MicroMarket Monitor 2Health News:Americas Colorants Market is Expected to Reach 2,006 Thousand MT in 2018 - New Report by MicroMarket Monitor 3Health News:Americas Colorants Market is Expected to Reach 2,006 Thousand MT in 2018 - New Report by MicroMarket Monitor 4Health News:Teen 'Growing Pains' May Persist For Years 2Health News:SAS Selects i2i Systems for Health Care Center Patient Referral Database 2Health News:SAS Selects i2i Systems for Health Care Center Patient Referral Database 3Health News:Weight Loss Destination, the Biggest Loser Resort in Utah, Rebrands as Fitness Ridge 2
... male veterans suffering from chronic obstructive pulmonary disease (COPD), ... cancer, researchers found that regular use of high dose ... cancer. ,David H. Au, M.D., M.S., of the ... along with five associates found that among 10,474 patients ...
... testosterone, which plays a key role in health and ... ,People suffering with Alzheimer's lack the ability to ... As the disease progresses, individuals may also experience changes ... agitation, as well as delusions or hallucinations. ...
... has over the years been a high source of nutrition ... that can be eaten in several forms, it is the ... With Easter just round the corner an animal rights group ... urging people not to eat eggs. ,Volunteers of ...
... fish varieties, is increasing all along the coastal regions in ... to it every year, it is estimated. // ... damage that pollution and global warming are inflicting on the ... of popular fish types, including grouper and barracuda, live near ...
... last year, has left Health Trusts short of nearly ?56million, ... from a local survey of health trusts show that almost ... money than they had expected to get under the new ... shortage, PCT may try to re allocate money from other ...
... overweight and obese individuals, the incidence of asthma increases ... weight, according to a meta-analysis of seven studies on ... first issue for April 2007 of the American Journal ... American Thoracic Society. ,E. Rand Sutherland, ...
Cached Medicine News:Health News:High Dose Inhaled Corticosteroid Use for COPD Could Cut Risk of Lung Cancer 2Health News:Global Warming Could Increase Exotic Fish Poisoning 2Health News:Asthma Incidence Shows a 50 Percent Increase in Fat People 2
(Date:7/31/2014)... WASHINGTON , July 31, 2014  CVS/pharmacy ... first pharmacy in the nation to earn the ... health care accreditation organization that establishes quality standards ... Longs Drug Store locations nationwide have earned this ... accreditation programs. Its Community Pharmacy Accreditation Program was ...
(Date:7/31/2014)... Mass., July 31, 2014 HeartWare International, ... innovator of less invasive, miniaturized circulatory support technologies that ... announced revenue of $70.1 million for the second quarter ... $50.8 million in revenue for the same period of ... ® Ventricular Assist Systems were sold globally compared ...
(Date:7/31/2014)... 2014 Second Quarter Total Revenue $2.0 billion; an increase of ... 4% for same store sales and 8% pro forma, excluding ... , 2014 Second Quarter GAAP EPS $0.37; Cash EPS $1.91, ... Operating Cash Flow $376 million; Adjusted Operating Cash Flow $500 ... Launched 17 new products in the U.S. year-to-date , ...
Breaking Medicine Technology:CVS/pharmacy Earns First-Ever Community Pharmacy Accreditation from URAC 2CVS/pharmacy Earns First-Ever Community Pharmacy Accreditation from URAC 3HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 2HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 3HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 4HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 5HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 6HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 7HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 8HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 9HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 10HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 11HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 12Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 2Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 3Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 4Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 5Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 6Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 7Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 8Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 9Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 10Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 11Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 12Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 13Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 14Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 15Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 16Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 17Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 18Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 19Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 20Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 21Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 22Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 23
... International Partnership for Microbicides, issued the following statement ... and effectiveness study of BufferGel and PRO2000 (0.5 ... Microbicide Trials Network, a worldwide collaborative group funded ... released final results from its Phase II/IIb safety ...
... Only Approved Platelet Producer in Europe Represents New ... Feb. 6 Amgen (Nasdaq: AMGN ... has granted marketing authorisation for Nplate(R) (romiplostim) for ... thrombocytopenic purpura (ITP) patients who are refractory to ...
Cached Medicine Technology:New PRO2000 HIV-Prevention Findings Important Milestone on Path Toward Development of Effective Vaginal Microbicide 2New PRO2000 HIV-Prevention Findings Important Milestone on Path Toward Development of Effective Vaginal Microbicide 3New PRO2000 HIV-Prevention Findings Important Milestone on Path Toward Development of Effective Vaginal Microbicide 4Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 2Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 3Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 4Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 5Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 6Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 7Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 8
Quick Release Holder designed for the 8000 Series Microtome to hold hardboard squares....
Steel Knife with box for the Series 8000 Sliding Microtome. C-Profile, 240 x 33 x13m, 22 Degree angle, tapped to accept holder for Shandon knife sharpener....
... new SureCut M3500 Radial Microtome has a look ... and a range of functions and capabilities that ... Based on years of experience and knowledge but ... the SureCut M3500 Microtome will be the answer ...
Spare fuse set...
Medicine Products: